Description:
Novel PPARδ Agonists for Bone Growth
Background
Osteoporosis is a silent disease of bones that affects tens of millions of people over the age of 50 with direct medical costs of over $31 billion yearly due to injuries from falls. With the aging population of the US there is a serious need for effective treatments to combat bone loss. There are currently no drugs developed to raise bone mass to normal levels only decrease the rate of loss. Current therapies have risk of serious complications such as avascular necrosis, stroke, risk of tumor growth or atypical femoral fractures.
Invention Description
Researchers at the University of Toledo have developed novel PPARδ Agonists which have osteogenic and chondrogenic properties without the serious side effects of current treatment regimens.
Applications
Increase bone formation in patients with osteoporosis, osteoarthritis, metabolic bone diseases or undergoing chemotherapy.
Advantages
- Increased osteoblast stimulation decreased osteoclast formation.
- Applicable across multiple cancer indications to help resist chemotherapy’s deleterious effects on bone growth.
- In vivo ovariectomy mouse study showed increase in osteoprotegerin and (μCT) measured normalization of bone density.
--------------------------------------------------------------------------------------------------------------------------------------------------
Lead Inventor: Bruce E. Heck
IP: US Patents 10181018B2, 10776461B2, 11524004B2
Further Information: Seth Smith, Patent Agent
Licensing Associate
seth.smith3@utoledo.edu
Office: 419-530-6229
